Pyrimido-diazepinone compounds and methods of treating disorders
The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.
1. A compound of formula V:
or a pharmaceutically acceptable salt thereof,
wherein,
X is hydrogen;
R 2 is hydrogen or alkyl;
R 3 is —OH or O-(alkyl);
R 4 is hydrogen or alkyl;
R 6 is hydrogen or alkyl; and
R′ is hydrogen.
2. The compound of claim 1 , wherein R 2 is H, methyl, or ethyl.
3. The compound of claim 1 , wherein R 6 is H.
4. The compound of claim 1 , wherein R 3 is —OCH 3 or —OCH 2 CH 3 .
5. The compound of claim 1 , wherein R 4 is methyl or ethyl.
6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.